
Immunovant Inc (IMVT) Stock Forecast & Price Target
Immunovant Inc (IMVT) Analyst Ratings
Bulls say
Immunovant Inc. is focused on its lead candidate, IMVT-1402, a potential IgG antibody inhibitor with promising prospects in treating autoimmune diseases. The company's strategic investment in research and development, reflected by a 49.7% year-over-year increase in G&A expenses, indicates a robust commitment to advancing its product pipeline, particularly in the large market for autoimmune conditions. With projected global peak sales of $775 million in generalized myasthenia gravis (gMG) based on conservative market penetration assumptions and the advantages of self-administration through an auto-injector, Immunovant’s business model suggests a favorable outlook for capturing market share and increasing profitability.
Bears say
Immunovant Inc experienced a significant year-over-year increase of 95.5% in research and development (R&D) expenses, amounting to $94.5 million, which fell short of the company's estimated expenses and indicates a growing financial burden. Additionally, the company reported a net loss of $111.1 million for the fiscal 3Q24, translating to a loss per share of $0.76, which not only exceeded previous estimates but also highlighted a deterioration in performance compared to the prior year's loss per share of $0.36. Furthermore, the emerging understanding that other antibody isotypes contribute to autoimmune diseases raises concerns regarding the efficacy of Immunovant's FcRn inhibition approach, suggesting potential challenges ahead in clinical development and increased operational risks.
This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunovant Inc (IMVT) Analyst Forecast & Price Prediction
Start investing in Immunovant Inc (IMVT)
Order type
Buy in
Order amount
Est. shares
0 shares